Who Owns Ligand Pharmaceuticals Stock?
NASDAQ: LGNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 118.32%
- Institutions (% of float)
- 121.09%
- Held by insiders
- 2.29%
- Institutional holders
- 580
- Institutions 97.7%
- Insiders 2.3%
- Public and other 0.0%
Who owns Ligand Pharmaceuticals stock?
Institutional investors own about 118.3% of Ligand Pharmaceuticals's shares, spread across 580 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 2.29% of LGND.
The largest institutional holders are Blackrock Inc. (15.56%), Invesco Ltd. (7.52%) and Vanguard Portfolio Management LLC (5.56%). Together, the top 10 institutions control 56.0% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their LGND positions and 6 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of LGND
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 3.11M | 15.56% | +0.4% |
| Invesco Ltd. | 1.50M | 7.52% | +25.1% |
| Vanguard Portfolio Management LLC | 1.11M | 5.56% | -2.3% |
| Janus Henderson Group Ltd. | 914.35K | 4.57% | -9.5% |
| Franklin Templeton, Inc. | 912.31K | 4.56% | +21.3% |
| Vanguard Capital Management LLC | 869.48K | 4.35% | -0.2% |
| State Street Corporation | 834.68K | 4.17% | +1.0% |
| FMR, LLC | 698.92K | 3.49% | -8.4% |
| Congress Asset Management Co | 658.56K | 3.29% | -0.2% |
| Geode Capital Management, LLC | 586.81K | 2.93% | -0.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of LGND
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 1.19M | 5.94% |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 633.70K | 3.17% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 605.72K | 3.03% |
| Franklin Custodian Funds-FRANKLIN DYNATECH FUND | 550.00K | 2.75% |
| iShares Trust-iShares Russell 2000 ETF | 518.42K | 2.59% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 436.82K | 2.18% |
| JANUS INVESTMENT FUND-Janus Henderson Triton Fund | 418.86K | 2.09% |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 337.67K | 1.69% |
| Fidelity Securities Fund-Fidelity Small Cap Value Fund | 277.26K | 1.39% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 276.59K | 1.38% |
Frequently asked questions
Who is the largest shareholder of Ligand Pharmaceuticals?
Blackrock Inc. is the largest institutional shareholder of LGND, owning 15.56% of shares outstanding (3.11M shares) as of its latest 13F filing.
What percentage of Ligand Pharmaceuticals is owned by institutions?
Institutions own about 118.3% of LGND shares and 121.1% of the public float.
How much of Ligand Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 2.29% of LGND shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.